Alex H Gifford1, Dana B Dorman2, Lisa A Moulton2, Jennifer E Helm2, Mary M Griffin2, Todd A MacKenzie3. 1. Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. 2. Translational Research Core, Dartmouth Lung Biology Center, Lebanon, New Hampshire, USA. 3. Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Abstract
BACKGROUND: Serum levels of hepcidin-25, a peptide hormone that reduces blood iron content, are elevated when patients with cystic fibrosis (CF) develop pulmonary exacerbation (PEx). Because hepcidin-25 is unavailable as a clinical laboratory test, we questioned whether a one-time serum iron level was associated with the subsequent number of days until PEx, as defined by the need to receive systemic antibiotics (ABX) for health deterioration. METHODS: Clinical, biochemical, and microbiological parameters were simultaneously checked in 54 adults with CF. Charts were reviewed to determine when they first experienced a PEx after these parameters were assessed. Time to ABX was compared in subgroups with and without specific attributes. Multivariate linear regression was used to identify parameters that significantly explained variation in time to ABX. RESULTS: In univariate analyses, time to ABX was significantly shorter in subjects with Aspergillus-positive sputum cultures and CF-related diabetes. Multivariate linear regression models demonstrated that shorter time to ABX was associated with younger age, lower serum iron level, and Aspergillus sputum culture positivity. CONCLUSIONS: Serum iron, age, and Aspergillus sputum culture positivity are factors associated with shorter time to subsequent PEx in CF adults.
BACKGROUND: Serum levels of hepcidin-25, a peptide hormone that reduces blood iron content, are elevated when patients with cystic fibrosis (CF) develop pulmonary exacerbation (PEx). Because hepcidin-25 is unavailable as a clinical laboratory test, we questioned whether a one-time serum iron level was associated with the subsequent number of days until PEx, as defined by the need to receive systemic antibiotics (ABX) for health deterioration. METHODS: Clinical, biochemical, and microbiological parameters were simultaneously checked in 54 adults with CF. Charts were reviewed to determine when they first experienced a PEx after these parameters were assessed. Time to ABX was compared in subgroups with and without specific attributes. Multivariate linear regression was used to identify parameters that significantly explained variation in time to ABX. RESULTS: In univariate analyses, time to ABX was significantly shorter in subjects with Aspergillus-positive sputum cultures and CF-related diabetes. Multivariate linear regression models demonstrated that shorter time to ABX was associated with younger age, lower serum iron level, and Aspergillus sputum culture positivity. CONCLUSIONS: Serum iron, age, and Aspergillus sputum culture positivity are factors associated with shorter time to subsequent PEx in CF adults.
Authors: Philip A Reid; David A McAllister; A Christopher Boyd; J Alastair Innes; David Porteous; Andrew P Greening; Robert D Gray Journal: Am J Respir Crit Care Med Date: 2015-01-15 Impact factor: 21.405
Authors: Catherine J Dobbin; Delwyn Bartlett; Kerri Melehan; Ronald R Grunstein; Peter T P Bye Journal: Am J Respir Crit Care Med Date: 2005-04-14 Impact factor: 21.405
Authors: Todd MacKenzie; Alex H Gifford; Kathryn A Sabadosa; Hebe B Quinton; Emily A Knapp; Christopher H Goss; Bruce C Marshall Journal: Ann Intern Med Date: 2014-08-19 Impact factor: 25.391
Authors: H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl Journal: N Engl J Med Date: 1994-09-08 Impact factor: 91.245
Authors: Elizabeta Nemeth; Seth Rivera; Victoria Gabayan; Charlotte Keller; Sarah Taudorf; Bente K Pedersen; Tomas Ganz Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: Nupur K Das; Andrew J Schwartz; Gabrielle Barthel; Naohiro Inohara; Qing Liu; Amanda Sankar; David R Hill; Xiaoya Ma; Olivia Lamberg; Matthew K Schnizlein; Juan L Arqués; Jason R Spence; Gabriel Nunez; Andrew D Patterson; Duxin Sun; Vincent B Young; Yatrik M Shah Journal: Cell Metab Date: 2019-11-07 Impact factor: 27.287
Authors: H F Hazlett; T H Hampton; D S Aridgides; D A Armstrong; J A Dessaint; D L Mellinger; A B Nymon; A Ashare Journal: Sci Rep Date: 2020-07-02 Impact factor: 4.379